April 28th 2025
Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on high-impact innovations.
Q&A With Miruna Sasu, president and CEO, COTA, Inc.
April 20th 2022From exposing disparities in care to guiding better patient outcomes to helping reign in the costs of care, the use of real-world data (RWD) in oncology can have far-reaching effects. Here’s how one RWD company exec is using her experience to help drive that change.
Q&A With Aoife Brennan, president and CEO of Synlogic, Inc.
March 16th 2022Brennan describes what her career journey in pharma has looked like as a woman, and what she feels can be done to improve opportunities for other females in pharma. She also talks about how advocacy and commitment can similarly be applied to improve the rare disease space.